Form 4: Acasti Pharma CEO Prashant Kohli Reports Stock Option Grant

Acasti Pharma's CEO, Prashant Kohli, reports the acquisition of stock options.

Summary

• Prashant Kohli, CEO of Acasti Pharma Inc., filed a Form 4 on May 8, 2024, reporting a transaction.
• On May 6, 2024, Kohli was granted 128,770 stock options with an exercise price of $2.96.
• These options vest quarterly over a 36-month period and expire on May 6, 2034.
• Following the transaction, Kohli directly owns 128,770 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine executive compensation disclosure.

Positives

• The grant of stock options to the CEO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize executives and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options to incentivize their leadership teams.
• The vesting schedule of 36 months is fairly typical for such grants.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the CEO successfully executes the company's strategy.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates